GenScript Biotech Global Forum London 2025

(1) GenScript Biotech Global Forum London 2025

The field of gene and cell therapy is experiencing unprecedented growth, driven by groundbreaking innovations in life sciences, medicine, and robust investment from global capital markets. To foster progress in this transformative field, the GenScript Biotech Global Forum London 2025 will convene on Thursday, 20 November 2025 in London, held in conjunction with the Jefferies London Healthcare Conference. With four successful iterations in San Francisco and London, the Forum has established itself as a premier gathering for top minds in cell and gene therapy.

Under the theme THE NEXT ERA OF CGT IS HERE, we are honored to invite leading experts from academia, industry, investment, and regulatory agencies to discuss the latest advancements in research, technological breakthroughs and evolving regulatory landscapes. This forum will bring together global thought leaders united in the mission to accelerate therapies that improve patient lives.

(2) Hot Topics

• NAVIGATING THE FUTURE OF CELL THERAPY: EVALUATING VARIED PATHWAYS IN CELL THERAPY INNOVATION FOR COMPREHENSIVE SECTOR INSIGHTS
• GENE THERAPHY AND mRNA THERAPEUTICS
• FROM LAB TO PATIENT: OVERCOMING CMC BARRIERS IN CELL AND GENE THERAPY MANUFACTURING
• INNOVATION AND INVESTMENT FOR CGT ​

(3) Schedule: (GMT Time Zone)

• Registration: 12:00 P.M.-1:30 P.M.

• Program: 1:30 P.M.- 6:30 P.M.

• Reception: 6:30 P.M.- 8:30 P.M.

(4) Part of Confirmed Speakers

• Dima Al-hadithi, Founder and Director of Minaret Consulting Limited and RareGenix Consulting Limited
• Michael Brinkman, Managing Director and Joint US Head of Biopharmaceuticals Investment Banking, Jefferies
• Michel Broker,Managing Director and Global Head of Pharma, UBS
• Luigi Calzolai, Scientific Officer, European Commission Joint Research Centre (JRC）
• Anna Cereseto, Head of Lab for Advanced Genome Editing Technologies, University of Trento, Co-Founder, Alia Therapeutics
• Matthieu Coutet, Partner, Sofinnova Biovelocita Strategy
• Daniela Couto, General Partner at BioGeneration Ventures
• Jonathan Esensten, Senior Advisor, Multiply Labs, and Director, Advanced Biotherapy Center, Sheba Medical Center
• Graeme Fielder, Chief Operating Officer, AviadoBio
• Miguel Forte, President and Board of Directors Chair of the International Society of Cell and Gene Therapy (ISCT)
• Miroslav Gasparek, CEO and Co-founder, Sensible Biotechnologies
• Marten Hansen, Head of the Laboratory for Cell Therapy at the Sanquin Blood Supply Foundation, CEO of the Amsterdam Cell Therapy Center, Secretary of the Dutch-Flemish ATMP Working Party
• Stephen Hansen, Director of Biopharma Intelligence, BioCentury
• Ying Huang, CEO, Legend Biotech
• Peter Jones, Director, Pengwin Consultancy
• Carl June, Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania
• Sergio Linares, Ph.D, Unit Head of RNA Science Automation, Sanofi
• Hongbo Lu, Founder and Managing Partner of NextBio Capital
• John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio
• Marcello Maresca, Senior Director of Genome Engineering department, AstraZeneca
• Craig Mello, Blais University Chair in Molecular Medicine, and co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, 2006 Nobel Prize in Physiology or Medicine
• Julen Oyarzabal, CSO of Syngoi Technologies SL
• Paula Río, Head of the Bone Marrow Aplasia Unit at CIEMAT/CIBERER/IIS-FJD
• Robin Shattock, Chair in Mucosal Infection and Immunity, Imperial College London
• Paul Stoffels, Former Chief Scientific Officer, Johnson & Johnson. Co-founder, Former CEO - Chair Galapagos NV
• Laura Stoppel, Partner on the Investment Team, RA Capital Management
• Jin Yin, PhD, CTO of CGT Technology Center, ProBio

We would like to extend to you a cordial invitation to join your peers at what promises to be a unique opportunity to share insights and collaborate on the global advancement of cell and gene therapy in London in November 2025.

*Program schedule and speakers are subject to change.

Highlights of Series Forum